Research Article

Association of RDW, NLR, and PLR with Atrial Fibrillation in Critical Care Patients: A Retrospective Study Based on Propensity Score Matching

Yao-Zong Guan, Rui-Xing Yin, Peng-Fei Zheng, Chun-Xiao Liu, Bi-Liu Wei, and Guo-Xiong Deng

1Department of Cardiology, Institute of Cardiovascular Diseases, The First Affiliated Hospital, Guangxi Medical University, Nanning, 530021 Guangxi, China
2Guangxi Key Laboratory Base of Precision Medicine in Cardio-Cerebrovascular Disease Control and Prevention, Nanning, 530021 Guangxi, China
3Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, Nanning, 530021 Guangxi, China

Correspondence should be addressed to Rui-Xing Yin; yinruixing@163.com

Received 21 November 2021; Revised 9 April 2022; Accepted 12 May 2022; Published 27 May 2022

Objective. Previous studies have shown inconsistent results in relation to the red cell distribution width (RDW), neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) of atrial fibrillation (AF). This retrospective study is aimed at detecting the association of RDW, NLR, and PLR with AF.

Methods. A total of 4717 critical care patients were screened from the Medical Information Mart for Intensive Care- (MIMIC-) III database. The patients were separated into the non-AF and AF groups. The imbalances between the groups were reduced using propensity score matching (PSM). ROC curves were generated to detect the diagnostic value of RDW, NLR, and PLR. Logistic regression analysis was used to detect the risk factors for AF.

Results. A total of 991 non-AF patients paired with 991 AF patients were included after PSM in this study. The RDW level in the AF group was significantly higher than that in the non-AF group (15.09 ± 1.93 vs. 14.14 ± 1.89, P = 0.017). Neither NLR nor PLR showed any significant difference between the two groups (P > 0.05 for each). According to ROC curve, RDW showed a very low diagnostic value of AF (AUC = 0.5341), and the best cutoff of RDW was 14.1 (AUC = 0.5257, sensitivity = 0.658, specificity = 0.395). Logistic regression analysis showed that an elevated RDW level increased 1.308-fold (95% CI = 1.077-1.588, P = 0.007) risk of AF. Neither elevated NLR nor elevated PLR was a significant risk factor for AF (OR = 0.993, 95% CI = 0.802-1.228, P = 0.945 for NLR; OR = 0.945, 95% CI = 0.763-1.170, P = 0.603 for PLR). Conclusions. Elevated RDW level but not NLR or PLR levels is associated with AF. RDW > 14.1 is a risk factor for AF, but its diagnostic capacity for AF is not of great value.

1. Introduction

With the improvement of technology and living standards, numerous countries have entered a period of aging. Atrial fibrillation (AF) is a progressive disease, and its prevalence increases with age, leading to cardiac dysfunction and cardio-embolic stroke [1, 2]. Early epidemiological research showed that the number of patients diagnosed with AF has reached at 33 billion globally and continues to increase. Moreover, it is estimated that 3-year societal costs were approximately €20,403 to €26,544 for a patient with AF [3, 4]. Although catheter ablation and cryoballoon ablation have achieved great success in the treatment of AF, the mechanism of AF remains unclear [5, 6], and we still need to invest significant methods in the screening, treatment, and management of AF.

Electrocardiography (ECG) is widely used to identify AF, but not all AF occurs during an ECG examination, even
During 24-hour or 72-hour monitoring, peripheral blood is a sample which is easy to obtain, and blood tests can detect latent diseases early. Thus, we have worked for a long time, aiming to identify hematologic markers of AF. Routine blood tests can provide basic information such as red blood cell (RBC), lymphocyte, neutrophil, and platelet count, and based on this information, several parameters like red cell distribution width (RDW), the neutrophil to lymphocyte ratio (NLR), and the platelet to lymphocyte ratio (PLR) can be calculated. RDW is a parameter reflecting the heterogeneity of RBC volume, which is expressed by the coefficient of variation of RBC volume size. The results in a previous follow-up study of mean 13.6 years on 27,124 general individuals suggested that RDW was associated with the incidence of AF. After being adjusted by age and sex, the incidence of AF was significantly associated with RDW (hazard ratio, HR = 1.26; 95% confidence interval, CI = 1.11–1.44 for fourth vs. first quartile of RDW), and this association was still strong after adjustment for potential confounding factors, including iron, vitamin B12 and folate intake, cardiovascular disease risk factors, and several hematological parameters (HR = 1.33, 95%CI = 1.16–1.53) [7]. Similarly, another study with 240,477 healthy volunteers followed up to 9 years also showed that higher RDW predicted onset of a wide range of common conditions, including AF. After being adjusted for age, sex, smoking status, educational attainment, hemoglobin, and mean corpuscular volume (MCV), the subgroup with RDW that ranged from 14.5 to 14.9% got a higher risk of AF vs. the subgroup with RDW that ranged from 12.5 to 12.9% (HR = 1.91, 95%CI = 1.58–2.30) [8].

NLR is an important indicator of inflammatory activity. A meta-analysis performed by Shao et al. [9] showed that a high NLR was associated with an increased risk of AF recurrence/occurrence with combined odds ratio (OR) of incident AF for baseline NLR level which was 1.25 (95%CI = 1.16–1.35) and 1.518 (95%CI = 1.076–2.142) for the post-NLR level (following coronary artery bypass graft, CABG; radio-frequency catheter ablation, RFCA; and cardioversion). A recent study conducted by Berkovitch et al. [10] revealed that the NLR was directly associated with new-onset AF, and Kaplan-Meier’s survival analysis consistently showed that patients with high NLR (≥2.83) had a significantly higher event rate compared with low NLR (<2.83, P = 0.006). In contrast, Gungor et al. [11] reported that no significant association was found between elevated NLR and AF (unadjusted OR = 1.21, 95%CI = 0.82–1.76, P = 0.32; and OR = 1.33, 95%CI = 0.68–2.58, P = 0.40) for gender, hypertension, body mass index (BMI), left atrial volume, hemoglobin, MCV, mean platelet volume, RDW, and high-sensitivity C-reactive protein).

Another blood parameter, PLR, has been associated with new-onset AF after CABG surgery, and PLR levels > 119.3 can predict postoperative AF with 64% sensitivity and 56% specificity (AUC = 0.634, P = 0.012) [12]. In addition, another study suggested that after directly current cardioversion, PLR was a risk factor associated with long-term AF recurrence with OR = 3.029 (95%CI = 1.013–9.055, P = 0.01) [13]. However, the results from a recent study were different from those of previous studies, suggesting that elevated PLR was not independently associated with AF in patients undergoing isolated CABG (P > 0.05, after being adjusted for age, sex, hypertension, and diabetes mellitus) [14].

The associations between NLR, PLR, and AF have been determined previously, but their diagnostic value for AF remains controversial. Although the results of the above studies were adjusted by several covariates, some baseline parameters were imbalanced, which may affect the real results. Patients in critical care always had multiple diseases, one of which was AF. To date, little is known about the association between RDW, NLR, and PLR and AF in critical care patients. Here, this retrospective study is aimed at detecting their relationships based on a large single-center database: Medical Information Mart for Intensive Care-III (MIMIC-III).

2. Materials and Methods

2.1. Data Source. The MIMIC-III database is a single-center database integrated with information on over 50,000 distinct hospital patients admitted to critical care units during 2001–2012. The demographic characteristics, diagnosis, admission time, death time, laboratory tests, and treatment outcomes were all integrated within 38 tables in this database [15]. Patients’ information had been blurred to prevent disclosure of private information. Access to the data of this database requires online training and certification examination online at the National Institutes of Health (NIH). One of the authors (Y.-Z. G.) has completed the training and passed the certification (certification number: 9016236).

2.2. Patients Selected and Stratification Method. Data from the patients, aged >16 years, who were first admitted to the critical care unit were collected continuously. Routine blood parameters and biochemistry parameters first measured within 24 h after admission were selected. Other records of vasoactive drugs (such as epinephrine, norepinephrine, and dopamine), hemodialysis, and mechanical ventilation used within 24 h after admissions were also selected in this study. Those diagnosed with leukemia and/or lymphoma and/or carried a white blood cell (WBC) count < 4.0 × 10^9/L or WBC > 12.0 × 10^9/L were excluded because these factors could affect the accuracy of the result. Patients diagnosed with cirrhosis, inflammation, and other infections were also excluded because they would affect neutrophil count, NLR, and platelet count. Patients who had no information on routine blood tests within 24 h after admission were also excluded. The patients finally included were divided into a non-AF group and an AF group, and the diagnosis of AF was defined according to ICD-9. NLR was calculated as neutrophil count/lymphocyte count, and PLR was calculated as platelet count/lymphocyte count. The estimated glomerular filtration rate (eGFR) was calculated based on serum creatinine (sCr) according to a previous study [16]. Structured query language with pgAdmin4 PostgreSQL 9.6 was used to screen out the data (https://www.postgresql.org/). Afterward, a propensity score matching (PSM, 1:1 matched) was used to reduce the imbalances of age, sex, and...
comorbidities between the groups with a caliper width of 0.02, and then, the imbalances of RBC counts, potassium, eGFR, blood urea nitrogen (Bun), smoker, acute myocardial infarction (AMI), and hemodialysis were reduced with a caliper width of 0.01 [17]. The flow chart of this study is shown in Figure 1.

2.3. Statistical Analysis. Continuous variables were presented as the mean ± standard deviation (SD) or medians with interquartile range (IQR) (if it was abnormally distributed), and categorical variables were presented as numbers and percentages. Continuous data were compared by one-way ANOVA or the Kruskal-Wallis test (if it was abnormally distributed), and categorical data were compared by the Chi-square test. ROC curves were used to detect the diagnostic value of RDW, NLR, and PLR. The cutoff was determined according to the corresponding value of the largest Youden index (Youden index = sensitivity + specificity – 1). Logistic regression analysis was performed to detect the risk factors for AF. The effect of risk factors was presented as an odds ratio (OR) with a 95% confidence interval (CI). Finally, the Pearson correlation coefficient was used to detect the factors correlated with RDW. The Stata software (version 14.0, USA) was used to perform the analysis, and two-sided P < 0.05 was set as significant.

3. Results

3.1. Patients’ Characteristics. Before PSM, a total of 4717 patients were screened from the MIMIC-III database. The AF group included 1305 patients (729 males, 55.9%), and the non-AF group included 3412 patients (1817 males, 53.3%). The distributions of age between the two groups were significantly different (P < 0.001). The rates of smoker, obesity, AMI, malignancy, pulmonary embolism (PE), and deep venous thrombosis (DVP) were not significantly different between the non-AF and AF groups (P > 0.05). The rates of other combinations were all higher in the AF than in the
### Table 1: Characteristics of the patients before propensity score matching (PSM).

| Parameter                          | Total   | Control | AF       | $t$/$\chi^2$ | $P$    |
|------------------------------------|---------|---------|----------|--------------|--------|
| **Number**                         | $n = 4717$ | $n = 3412$ | $n = 1305$ |              |        |
| Gender (male/female)               | 2546/2171 | 1817/1595 | 729/576  | 0.108        | 0.110  |
| Age (n %)                          |         |         |          |              |        |
| <45 years                          | 691 (14.6) | 669 (19.6) | 22 (1.7)  | 644.989      | <0.001 |
| 45-59 years                        | 1095 (23.2) | 965 (28.3) | 130 (10.0) |              |        |
| 60-74 years                        | 1378 (29.2) | 958 (28.1) | 420 (32.2) |              |        |
| ≥75 years                          | 1553 (32.9) | 820 (24.0) | 733 (56.2) |              |        |
| Smoker                             | 1514 (32.1) | 1088 (31.9) | 426 (32.6) | 0.248        | 0.619  |
| Drinker                            | 391 (8.3) | 334 (9.8) | 57 (4.4)  | 36.493       | <0.001 |
| **Complications (n %)**            |         |         |          |              |        |
| Hypertension                       | 1928 (40.9) | 1354 (39.7) | 574 (44.0) | 7.226        | 0.007  |
| Diabetes mellitus                  | 1304 (27.6) | 901 (26.4) | 403 (30.9) | 9.448        | 0.002  |
| CAD                                | 1266 (26.8) | 772 (22.6) | 494 (37.9) | 111.484      | <0.001 |
| Heart failure                      | 1375 (29.1) | 704 (20.6) | 671 (51.4) | 433.154      | <0.001 |
| Cardiogenic shock                  | 109 (2.3) | 56 (1.6) | 53 (4.1)  | 24.490       | <0.001 |
| Hyperlipidemia                     | 1477 (31.3) | 984 (28.8) | 493 (37.8) | 35.065       | <0.001 |
| Obesity                            | 119 (2.5) | 79 (2.3) | 40 (3.1)  | 2.158        | 0.142  |
| Hyperthyroidism                    | 414 (8.8) | 268 (7.9) | 146 (11.2) | 13.098       | <0.001 |
| Pneumonia                          | 829 (17.6) | 563 (16.5) | 266 (20.4) | 9.823        | 0.002  |
| COPD                               | 129 (2.7) | 82 (2.4) | 47 (3.6)  | 5.095        | 0.024  |
| Liver disease                      | 351 (7.4) | 281 (8.2) | 70 (5.4)  | 11.302       | <0.001 |
| Chronic kidney diseases            | 622 (13.2) | 362 (10.6) | 260 (19.9) | 71.530       | <0.001 |
| Malignancy                         | 941 (19.9) | 658 (19.3) | 283 (21.7) | 3.407        | 0.065  |
| Thrombosis                         | 1065 (22.6) | 708 (20.8) | 357 (27.4) | 23.566       | <0.001 |
| AMI                                | 212 (4.5) | 152 (4.5) | 60 (4.6)  | 0.045        | 0.832  |
| Stroke                             | 175 (3.7) | 106 (3.1) | 69 (5.3)  | 12.566       | <0.001 |
| PE                                 | 154 (3.3) | 117 (3.4) | 37 (2.8)  | 1.054        | 0.305  |
| DVT                                | 96 (2.0) | 68 (2.0) | 28 (2.1)  | 0.110        | 0.740  |
| Other thrombosis                   | 588 (12.5) | 385 (11.3) | 203 (15.6) | 15.787       | <0.001 |
| Blood glucose (mg/dL)              | $138.02 \pm 68.17$ | $137.87 \pm 68.88$ | $138.52 \pm 67.68$ | $-0.713$     | 0.460  |
| RBC count ($\times 10^{12}$)       | $3.75 \pm 0.71$ | $3.76 \pm 0.71$ | $3.73 \pm 0.71$ | $0.981$     | 0.327  |
| MCV(fL)                            | $89.90 \pm 7.01$ | $89.82 \pm 7.15$ | $90.10 \pm 6.61$ | $-1.228$     | 0.219  |
| Hemoglobin (g/dL)                  | $11.35 \pm 2.09$ | $11.39 \pm 2.10$ | $11.25 \pm 2.07$ | $2.109$     | 0.035  |
| RDW                                | $14.91 \pm 2.10$ | $14.81 \pm 2.14$ | $15.19 \pm 1.99$ | $-5.658$     | <0.001 |
| WBC count ($\times 10^{9}$)        | $8.40 \pm 2.15$ | $8.38 \pm 2.16$ | $8.43 \pm 2.13$ | $-0.726$     | 0.468  |
| Platelet count ($\times 10^{9}$)   | $214.85 \pm 98.86$ | $216.23 \pm 102.85$ | $211.25 \pm 87.49$ | $1.548$     | 0.122  |
| Neutrophil count                   | $6.53 \pm 2.16$ | $6.49 \pm 2.16$ | $6.63 \pm 2.15$ | $-2.083$     | 0.037  |
| Lymphocyte count                   | $1.19 \pm 0.70$ | $1.22 \pm 0.73$ | $1.13 \pm 0.63$ | $4.057$      | <0.001 |
| NLR                                | $6.01 (6.61)$ | $5.89 (6.50)$ | $6.35 (6.83)$ | $9.938$      | 0.002  |
| PLR                                | $185.54 (186.34)$ | $183.56 (187.69)$ | $190.69 (179.51)$ | $7.646$     | 0.006  |
| Sodium (mmol/L)                    | $138.64 \pm 4.84$ | $138.64 \pm 4.90$ | $138.62 \pm 4.67$ | $0.130$     | 0.896  |
| Potassium (mmol/L)                 | $4.13 \pm 0.73$ | $4.09 \pm 0.73$ | $4.22 \pm 0.71$ | $-5.320$     | <0.001 |
| eGFR (mL/min/1.73 m$^2$)            | $70.36 (53.00)$ | $76.13 (53.87)$ | $57.53 (44.39)$ | $205.801$  | <0.001 |
| Bun (mg/dL)                        | $19.0 (18.0)$ | $17.0 (16.0)$ | $24.0 (20.0)$ | $241.124$   | <0.001 |
| SOFA score                         | 4 (4) | 3 (4) | 4 (4) | 54.390       | <0.001 |
| Vasoactive drugs (n %)             | 237 (5.0) | 151 (4.4) | 86 (6.6) | 9.268        | 0.002  |
| Warfarin (n %)                     | 161 (3.4) | 61 (1.8) | 100 (7.7) | 98.832       | <0.001 |
non-AF groups except for liver diseases (Table 1, \( P < 0.05 \) for all). After PSM, a total of 991 paired patients were matched between the two groups. The differences in the distribution of age and the rate of combinations between different groups were balanced (Table 2, \( P > 0.05 \) for all).

3.2. Laboratory Parameters and Other Factors. Table 1 shows that the levels of RDW, NLR, PLR, potassium, and Bun; neutrophil count; and the rates of vasoactive drugs use, warfarin, aspirin, and hemodialysis were higher in the AF compared with the non-AF groups (\( P < 0.05 \) for all). The eGFR level was lower in the AF than that in the non-AF groups (\( P < 0.001 \), Table 1). After PSM, the differences in neutrophil count; the levels of NLR, PLR, potassium, bun, and eGFR; and the rates of use of vasoactive drugs and hemodialysis were balanced (\( P > 0.05 \) for all). However, the levels of RDW and the rates of warfarin and aspirin use remained higher in the AF than in the non-AF groups (\( P < 0.001 \)).

3.3. ROC Curve of RDW for Diagnosis of AF. Figures 2 and 3(a) show that before and after PSM, the diagnostic value of elevated RDW levels for AF was low (\( AUC = 0.5788 \) before PSM and 0.5341 after PSM). We selected RDW = 14.1 as the cutoff according to the max Youden index and found that the AUC of the ROC curve was 0.5257 (sensitivity = 0.658, 1 – specificity = 0.641, Figure 3(b)). In the subgroup of age distribution, the diagnostic value of RDW for AF was the highest in the age < 45-year group (\( AUC = 0.6790 \)), but a significant difference was not found among all the subgroups (\( P > 0.05 \), Figure 4).

3.4. Risk Factors for AF. Logistic regression analysis was used to detect the risk factors for AF. RDW was an independent risk factor for AF (\( OR = 1.248, 95\% CI = 1.039-1.499, P = 0.018 \)). In addition, the risk decreased after adjusting for age and sex (\( OR = 1.059, 95\% CI = 1.011-1.109, P = 0.016 \)), but increased after adjusting for age, sex, combinations, laboratory examination parameters, and use of hemodialysis and mechanical ventilation (\( OR = 1.308, 95\% CI = 1.077-1.588, P = 0.007 \), Table 3).

3.5. Related Factors of RDW. According to the results of Spearman analysis, RDW was weakly correlated with AF (\( r^2 = 0.059, P < 0.001 \)). RDW was correlated with several other diseases, such as hypertension (\( r^2 = -0.188, P < 0.001 \)), hyperlipidemia (\( r^2 = -0.123, P < 0.001 \)), and diabetes (\( r^2 = 0.123, P < 0.001 \)), and several laboratory examination parameters, such as lymphocyte count (\( r^2 = -0.161, P < 0.001 \)), platelet count (\( r^2 = -0.052, P = 0.020 \)), and bun level (\( r^2 = -0.052, P < 0.001 \)). The use of mechanical ventilation was correlated with RDW, NLR, and PLR (\( r^2 = 0.115, 0.168, \) and 0.114, respectively, \( P < 0.001 \) for all). The correlations among the factors are shown in Figure 5, and details are provided in the Supplementary Materials.

4. Discussion

AF is a high-morbidity cardiovascular disease that leads to deterioration of cardiac function and cardiogenic stroke. Previous studies indicate that AF is highly prevalent in critical care patients and can be served as a marker of poor prognosis and increased mortality [18, 19]. To date, the mechanism of AF has not been well elucidated, but it has been accepted by many experts and scholars that the inflammatory response plays an important role in the formation and maintenance of AF, and decrease of cardiovascular event rates can be found after anti-inflammatory therapy [20, 21]. An increasing number of biomarkers of AF, such as interleukin-6 (IL-6), IL-8, and N-terminal probrain natriuretic peptide (NT-proBNP), have been reported in recent decades [22, 23]. In addition, overload capacity of the atrium results in changes in myocardial electrical and anatomical structure, increasing the risk of AF [24, 25]. In several previous studies, the associations between several hematological parameters, such as RDW, NLR, PLR, and AF, were inconsistent. Our findings indicate that an elevated RDW but neither NLR nor PLR level is significantly associated with AF, and it is an independent risk factor for AF. However, the diagnostic capacity of RDW for AF is not of great value. The data of our study provide more evidence for further research on RDW, NLR, and PLR with AF.

RDW is an easily accessible hematologic parameter, reflecting the distribution of erythrocyte volume. RDW has been indicated as a biomarker of inflammation and is associated with several cardiovascular events, such as myocardial infarction, atherosclerosis, heart failure, AF, and left atrial thrombus [26–31]. Data from a recent study showed that RDW increased with enlargement of the left atrium and was independently associated with AF progression [32]. This result indicated that RDW might reflect the volume of the left atrium. Our findings were consistent to previous reports that the RDW level was significantly higher in the AF group compared with the non-AF groups. This result suggested that the inflammation in the AF group may be more active and reflect the increased RDW levels. What is more, RDW has also been associated with chronic obstructive pulmonary
Table 2: Characteristics of the patients after PSM (1:1).

| Parameter                      | Total      | Control    | AF         | $F/\chi^2$ | $P$   |
|-------------------------------|------------|------------|------------|------------|-------|
| Number                        | $n = 1982$ | $n = 991$  | $n = 991$  |            |       |
| Gender (male/female)          | 910/1072   | 468/532    | 442/549    | 1.373      | 0.241 |
| Age (n (%))                   |            |            |            |            |       |
| <45 years                     | 40 (2.0)   | 23 (2.3)   | 17 (1.7)   | 5.385      | 0.146 |
| 45-59 years                   | 235 (11.9) | 132 (13.3) | 103 (10.4) |            |       |
| 60-74 years                   | 671 (33.9) | 333 (33.6) | 338 (34.1) |            |       |
| ≥75 years                     | 1036 (52.2)| 503 (50.8) | 533 (53.8) |            |       |
| Smoker                        | 437 (22.0) | 213 (21.5) | 224 (22.6) | 0.355      | 0.551 |
| Drinker                       | 94 (4.7)   | 50 (5.0)   | 44 (4.4)   | 0.402      | 0.526 |
| Complications (n (%))         |            |            |            |            |       |
| Hypertension                  | 887 (44.8) | 437 (44.1) | 450 (45.4) | 0.345      | 0.557 |
| Hyperlipidemia                | 714 (36.0) | 342 (34.5) | 372 (37.5) | 1.970      | 0.160 |
| Obesity                       | 55 (2.8)   | 28 (2.8)   | 27 (2.7)   | 0.019      | 0.891 |
| CAD                           | 736 (37.1) | 364 (36.7) | 372 (37.5) | 0.138      | 0.710 |
| Heart failure                 | 908 (45.8) | 452 (45.6) | 456 (46.0) | 0.033      | 0.857 |
| Cardiogenic shock             | 72 (3.6)   | 33 (3.3)   | 39 (3.9)   | 0.519      | 0.471 |
| Diabetes mellitus             | 611 (30.8) | 316 (31.9) | 295 (29.8) | 1.043      | 0.307 |
| Hyperthyroidism               | 209 (10.5) | 98 (9.9)   | 111 (11.2) | 0.904      | 0.342 |
| Pneumonia                     | 365 (18.4) | 180 (18.2) | 185 (18.7) | 0.084      | 0.772 |
| COPD                          | 66 (3.3)   | 33 (3.3)   | 33 (3.3)   | 0.000      | 1.000 |
| Liver disease                 | 108 (5.4)  | 58 (5.9)   | 50 (5.0)   | 0.627      | 0.429 |
| Chronic kidney diseases       | 341 (17.2) | 168 (17.0) | 173 (17.5) | 0.089      | 0.766 |
| Malignancy                    | 415 (20.9) | 196 (19.8) | 219 (22.1) | 1.612      | 0.204 |
| Thrombosis                    | 554 (28.0) | 276 (27.9) | 278 (28.1) | 0.010      | 0.920 |
| AMI                           | 118 (6.0)  | 61 (6.2)   | 57 (5.8)   | 0.144      | 0.704 |
| Stroke                        | 105 (5.3)  | 51 (5.1)   | 54 (5.4)   | 0.910      | 0.764 |
| PE                            | 53 (2.7)   | 24 (2.4)   | 29 (2.9)   | 0.485      | 0.486 |
| DVT                           | 28 (1.4)   | 11 (1.1)   | 17 (1.7)   | 1.304      | 0.253 |
| Other thrombosis              | 292 (14.7) | 146 (14.7) | 146 (14.7) | 0.000      | 1.000 |
| Blood glucose (mg/dL)         | 140.89 ± 65.08 | 142.63 ± 65.48 | 139.15 ± 64.67 | 1.190      | 0.234 |
| RBC count (×10^{12})          | 3.71 ± 0.68 | 3.72 ± 0.65 | 3.72 ± 0.72 | 0.025      | 0.980 |
| MCV(fL)                       | 90.08 ± 6.84 | 90.04 ± 7.10 | 90.12 ± 6.57 | -0.236    | 0.813 |
| Hemoglobin (g/dL)             | 11.24 ± 2.03 | 11.24 ± 1.96 | 11.24 ± 2.10 | 0.059      | 0.953 |
| RDW                           | 14.99 ± 1.92 | 14.89 ± 1.91 | 15.09 ± 1.93 | -2.380    | 0.017 |
| WBC count (×10^{9})           | 8.45 ± 2.11 | 8.49 ± 2.08 | 8.42 ± 2.13 | 0.742      | 0.458 |
| Platelet count (×10^{9})      | 211.93 ± 94.29 | 214.21 ± 98.10 | 209.65 ± 90.31 | 1.076      | 0.282 |
| Neutrophil count              | 6.60 ± 2.14 | 6.59 ± 2.13 | 6.61 ± 2.16 | -0.227     | 0.821 |
| Lymphocyte count              | 1.13 ± 0.66 | 1.15 ± 0.68 | 1.12 ± 0.64 | 0.742      | 0.458 |
| NLR                           | 6.44 (6.74) | 6.45 (6.19) | 6.42 (6.54) | 0.001      | 0.980 |
| PLR                           | 194.43 (184.31) | 195.97 (185.57) | 190.69 (183.71) | 0.015      | 0.903 |
| Sodium                        | 138.80 ± 4.72 | 138.63 ± 4.64 | 138.73 ± 4.80 | 0.643      | 0.521 |
| Potassium                     | 4.17 ± 0.72 | 4.17 ± 0.75 | 4.18 ± 0.67 | -0.261     | 0.794 |
| eGFR                          | 58.61 (44.53) | 58.61 (46.69) | 58.61 (43.41) | 0.182      | 0.670 |
| Bun                           | 23 (20)     | 23 (21)    | 23 (19)    | 3.037      | 0.081 |
| SOFA score                    | 4 (4)       | 4 (4)      | 4 (4)      | 2.286      | 0.131 |
| Vasoactive drugs (n (%))      | 111 (5.60)  | 59 (5.95)  | 52 (5.25)  | 0.468      | 0.494 |
| Warfarin (n (%))              | 85 (4.3)    | 16 (1.6)   | 69 (7.0)   | 34.528     | <0.001 |
After PSM was balanced, other factors, such as COPD and stroke, were balanced between the AF and the non-AF groups, and the difference in RDW between the two groups remained significant, providing an evidence for the association between RDW and AF. The results of logistic regression analysis show us that RDW may be an independent risk factor for AF, which is similar to those noted in previous reports [35]. In the present study, as shown in Figures 2 and 3, ROC curves did not show a reliable diagnostic value of

### Table 2: Continued.

| Parameter                        | Total       | Control    | AF          | $F/\chi^2$ | $P$   |
|----------------------------------|-------------|------------|-------------|------------|-------|
| Aspirin ($n$ (%))                | 339 (17.1)  | 151 (15.2) | 188 (19.0)  | 4.872      | 0.027 |
| Hemodialysis ($n$ (%))           | 96 (4.8)    | 51 (5.1)   | 45 (4.5)    | 0.394      | 0.530 |
| Mechanical ventilation ($n$ (%)) | 629 (31.7)  | 306 (30.9) | 323 (32.6)  | 0.673      | 0.412 |

CAD: coronary artery disease; AMI: acute myocardial infarction; PE: pulmonary venous embolism; DVT: deep vein thrombosis; COPD: chronic obstructive pulmonary disease; MCV: mean corpuscular volume; RDW: red cell distribution width; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; eGFR: estimated glomerular filtration rate; Bun: blood urea nitrogen; SOFA: Sequential Organ Failure Assessment.

**Figure 2:** ROC curve of different parameters for atrial fibrillation before and after PSM: (a) before PSM; (b) after PSM. RDW: red cell distribution width; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio.
RDW for AF. This finding may be explained by the fact that RDW can act as a marker of inflammation with low specificity, and the notion can be explored based on its associations with several diseases reported before [36–38]. In addition, RDW was measured as the width (fL) of the erythrocyte distribution curve at a relative height of 20% above the baseline (RDW-SD) in our study but not the coefficient of variation (RDW-CV); the latter was used in many other studies. In contrast to RDW-CV, RDW-SD is independent of MCV, which means the accuracy of the results may be biased because different measures of RDW were used.

It was reported that in general population, the elevated RDW was associated with the all-cause mortality, and the HR increased with the elevation of RDW, even after being adjusted for confounding factors including age, sex, BMI, smoking, diabetes, MCV, and several other parameters. In addition, the results suggested that there were significant differences of BMI and smoker among different RDW subgroups [39]. Elevated RDW was also used as a predictor of poor prognosis of anticoagulation response in patients with AF and the impatient adults with SARS-CoV-2 infection [40, 41]. In a previous study, adjusted OR value of metabolic syndrome was lower at the third and fourth quartile of RDW in males, and RDW might play a mediatory role in the relationship between waist circumference and the dysmetabolic outcomes in obese people [42]. Another large-size study reported that the patients got significantly increased risk of new-onset AF with obesity (HR = 1.327), overweight (HR = 1.123), and upper normal (HR = 1.040) [43]. However, there are also different voices. “Obesity paradox” was used to present that obesity was associated with the reduced risk of all-cause death, and overweight had been associated with significantly reduced risk of AF (HR 0.82, 95%CI = 0.73–0.89, P < 0.001) [44]. In the current study, neither before nor after PSM, there was no significant difference in the ratios of obesity between AF and non-AF groups. We also took the effect of obesity on RDW and AF into consideration and included it as the covariate in the analysis of the association of RDW and AF. We found that the RDW in the AF group was still significantly higher than that in the non-
Disease Markers

Figure 4: ROC curve of RDW in different age subgroups for atrial fibrillation. AUC: area under ROC curve; RDW: red cell distribution width.

Table 3: Risk factors of atrial fibrillation.

| Variables                      | Unadjusted OR (95% CI) | $P$ | Adjusted OR (95% CI)$^a$ | $P_a$ | Adjusted OR (95% CI)$^b$ | $P_b$ |
|--------------------------------|------------------------|-----|-------------------------|-------|-------------------------|-------|
| Male gender                    | 1.111 (0.931-1.326)    | 0.241 | 1.131 (0.947-1.352)    | 0.175 | 1.158 (0.964-1.391)    | 0.118 |
| Age > 75 years                 | 1.129 (0.946-1.347)    | 0.177 | 1.147 (0.960-1.371)    | 0.130 | 1.114 (0.926-1.340)    | 0.252 |
| Smoking                        | 1.067 (0.863-1.319)    | 0.551 | 1.055 (0.852-1.305)    | 0.624 | 1.040 (0.836-1.293)    | 0.725 |
| Drinking                       | 0.874 (0.577-1.324)    | 0.526 | 0.896 (0.590-1.361)    | 0.606 | 0.882 (0.576-1.349)    | 0.562 |
| Hypertension                   | 1.054 (0.883-1.291)    | 0.477 | 1.055 (0.884-1.260)    | 0.551 | 1.064 (0.883-1.281)    | 0.517 |
| Diabetes mellitus              | 0.905 (0.748-1.096)    | 0.307 | 0.909 (0.751-1.101)    | 0.331 | 0.856 (0.701-1.047)    | 0.130 |
| Coronary artery diseases       | 1.035 (0.863-1.242)    | 0.710 | 1.022 (0.851-1.227)    | 0.816 | 1.019 (0.830-1.250)    | 0.860 |
| Hyperlipidemia                 | 1.140 (0.949-1.370)    | 0.295 | 1.140 (0.949-1.370)    | 0.162 | 1.162 (0.952-1.418)    | 0.139 |
| Obesity                        | 0.964 (0.564-1.647)    | 0.891 | 1.042 (0.605-1.795)    | 0.883 | 1.052 (0.602-1.838)    | 0.860 |
| Heart failure                  | 1.016 (0.852-1.213)    | 0.857 | 1.027 (0.860-1.226)    | 0.772 | 0.999 (0.829-1.205)    | 0.994 |
| Cardiogenic shock              | 1.189 (0.742-1.907)    | 0.472 | 1.210 (0.754-1.941)    | 0.430 | 1.2360 (0.759-2.012)   | 0.394 |
| Pneumonia                      | 1.034 (0.824-1.298)    | 0.754 | 1.034 (0.824-1.299)    | 0.771 | 1.015 (0.798-1.291)    | 0.903 |
| COPD                           | 1.000 (0.612-1.634)    | 1.000 | 0.995 (0.608-1.627)    | 0.983 | 1.025 (0.621-1.693)    | 0.923 |
| Hyperthyroidism                | 1.149 (0.862-1.532)    | 0.342 | 1.164 (0.869-1.558)    | 0.308 | 1.156 (0.861-1.552)    | 0.336 |
| Thrombosis                     | 1.010 (0.830-1.229)    | 0.920 | 1.009 (0.829-1.228)    | 0.930 | 1.011 (0.822-1.243)    | 0.918 |
| Hemodialysis                   | 0.877 (0.581-1.322)    | 0.530 | 0.889 (0.588-1.342)    | 0.575 | 0.847 (0.553-1.298)    | 0.446 |
| Mechanical ventilation         | 1.082 (0.896-1.308)    | 0.412 | 1.088 (0.900-1.315)    | 0.384 | 1.099 (0.896-1.349)    | 0.366 |
| RDW > 14.1                    | 1.248 (1.039-1.499)    | 0.018 | 1.059 (1.011-1.109)    | 0.016 | 1.308 (1.077-1.588)    | 0.007 |
| NLR ≥ 6.44                     | 0.984 (0.825-1.173)    | 0.857 | 1.001 (0.993-1.101)    | 0.772 | 0.993 (0.802-1.228)    | 0.945 |
| PLR ≥ 194.43                   | 0.964 (0.809-1.150)    | 0.686 | 1.000 (0.999-1.000)    | 0.905 | 0.945 (0.763-1.710)    | 0.603 |

COPD: chronic obstructive pulmonary disease; RDW: red cell distribution width; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio. $P_a$: adjusted by age and gender; $P_b$: adjusted by age, gender, smoking, drinking, combinations, laboratory examination parameters, use of hemodialysis, and mechanical ventilation.
AF group. In addition, in the Spearman analysis, the correlation value of obesity and RDW and the value of obesity and AF were small. But, in some degree, however, the number of the obesity was little, and its real effects on the RDW and AF may be underestimated. In addition, the correlation analysis in Figure 5 showed that RDW was correlated with several factors, but their interrelationship needs further determination. Thus, the evidence of using RDW as a sensitive and accurate indicator for the diagnosis of AF is not sufficient.

NLR and PLR also reveal inflammatory activity, which can be used as a candidate blood-based inflammatory biomarker that is inexpensive and readily available. Bazoukis et al. [22, 23] indicated that the NLR may have the capacity to predict the recurrence of AF in patients undergoing catheter ablation. Recent studies have reported inconsistent findings of the association between a high NLR and postoperative AF. Excessive PLR levels may be a predictor of poor outcomes in patients with cardiovascular disease [45–49]. However, Luo et al. [50] suggested that after mitral valve surgery, recurrent AF patients got a higher NLR and PLR than those nonrecurrence patients, but the diagnostic power of NLR for AF recurrence is not high (AUC = 0.643, 95% CI = 0.513-0.773, P = 0.036), and PLR was not a significant predictor of AF recurrence (AUC = 0.620, 95%CI = 0.492-0.748, P = 0.079). Similarly, Ding et al. [51] reported that increased NLR was an independent predictor of nonvalvular AF recurrence vs. normal NLR after radiofrequency ablation (HR = 1.438, 95% CI: 1.036-1.995, P < 0.05). In the present study, the NLR and PLR levels between the AF and the non-AF groups were all different at first analysis. However, after PSM, although the NLR and PLR were highly increased in the AF compared with the non-AF groups, the difference was not significant. Spearman analysis showed that NLR and PLR were correlated with several other factors, such as
glucose level, heart failure, and hyperlipidemia, and NLR was also correlated to PLR with a high correlation coefficient $= 0.705$. In addition, the above parameters were both based on the lymphocyte count, and the Spearman analysis also suggested that lymphocytes were correlated with several diseases and other parameters. Compared to single count of neutrophil, lymphocyte, and thrombocyte, NLR and PLR were more stable, integrating the detrimental effects of neutrophil elevation, thrombocytosis (reflecting inflammation), and lymphopenia (a marker of physiological stress). Thus, although NLR and PLR reflect the activity of inflammation to some degree, these parameters are influenced by many factors. In the present study, the patients were selected from the critical care unit, and these patients always had several other diseases that may affect the inflammatory reaction. Therefore, the diagnostic capability of NLR and PLR for AF and their association with AF may be overestimated or underestimated, and more large-size studies are still needed to expose their relationship.

Both smoking and drinking also were the risk factors for AF. A meta-analysis showed that smoking was associated with AF with a summary relative risk (RR) $= 1.14$ (95%CI $= 1.10 - 1.20$) per 10 cigarettes per day, and RR $= 1.16$ (95%CI $= 1.09 - 1.25$) per 10 pack-years [52]. Another cross-sectional analysis revealed that there was an 18% increase of AF incidence in offspring with every pack/day increase in parental smoking (adjusted HR $= 1.18$, 95%CI $= 1.00 - 1.39$, $P = 0.04$) [53]. In context to alcohol, the HR for one drink (12 g) per day was 1.16 (95%CI $= 1.11 - 1.22$, $P < 0.001$), and abstinence from alcohol reduced AF recurrences [54, 55]. The mechanism that how smoking and drinking could increase the risk of AF remains unclear, and one reason to date is that tobacco and alcohol promote atrial myocardial remodeling, increase atrial fibrosis, damage atrial matrix, and then promote the formation of AF [56]. The ratio of smoker was higher in the AF group than in the non-AF group either before or after PSM in our study, though the difference was not significant. When it comes to drinking, the number of drinkers was significantly larger in non-AF than that in AF groups, but the difference was balanced after PSM. Our final analysis suggested that smoking and drinking would not increase the risk of AF. The reason is mainly because we balanced these parameters, aiming to detect the association of RDW, NLR, and PLR with AF without interference from other factors; and the number of drinker was not large enough. In addition, the patients included in the current study were all selected from critical care unit; thus, our results may be inconsistent with those in previous studies.

There are several limitations in the current study. First, the patients selected in this work were obtained from the critical care unit of a single center, and the findings may not apply to other populations. Second, the diagnosis was determined according to ICD-9; some patients may inevitably be left out. Finally, although several imbalance factors were adjusted, some potential factors may still affect these results.

5. Conclusions

Increased RDW level (RDW $> 14.1$) but not NLR or PLR is significantly associated with AF. RDW $> 14.1$ may serve as an independent risk factor for AF, but its diagnostic capacity for AF is still not large enough.

Abbreviations

| Abbreviation | Description                                                                 |
|--------------|-----------------------------------------------------------------------------|
| AF           | Atrial fibrillation                                                         |
| RDW          | Red cell distribution width                                                 |
| NLR          | Neutrophil to lymphocyte ratio                                              |
| PLR          | Platelet to lymphocyte ratio                                                |
| MIMIC        | Medical Information Mart for Intensive Care                                |
| PSM          | Propensity score matching                                                   |
| AMI          | Acute myocardial infarction                                                 |
| PE           | Pulmonary embolism                                                          |
| DVT          | Deep vein thrombosis                                                        |
| COPD         | Chronic obstructive pulmonary disease                                       |
| CKD          | Chronic kidney disease                                                     |
| SOFA         | Sequential Organ Failure Assessment                                         |
| Bun          | Blood urea nitrogen                                                         |
| sCr          | Serum creatinine                                                            |
| eGFR         | Estimated glomerular filtration rate                                        |
| SD           | Standard deviation                                                          |
| IQR          | Interquartile range                                                         |
| CVD          | Cardiovascular diseases                                                    |
| OR           | Odds ratio                                                                  |
| HR           | Hazard ratio                                                                |
| RR           | Relative risk                                                               |
| CI           | Confidence interval                                                        |
| AUC          | Area under the curve                                                       |

Data Availability

Full data set is available from the author at guan_yz1007@163.com. However, reanalysis of the full data needs to be approved by MIMIC-III Institute.

Ethical Approval

In this study, the data of patients were only retrospectively collected for analysis, and intervention and treatment were not involved. In addition, patients’ information had been blurred when MIMIC-III database was constructed. Author Y.-Z. G. gained access to document the database after online training including ethics examination at the National Institutes of Health (NIH).

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

Y.-Z.G. conceived the study, participated in the design, performed the statistical analyses, and drafted the manuscript. R.-X.Y. conceived the study, participated in the design, and helped to draft the manuscript. P.-F.Z. and C.-X.L. contributed in formal analysis. B.-L.W. and G.-X.D. helped to draft the manuscript. All authors read and approved the final manuscript.
Acknowledgments
This study was supported by the Science Foundation of Guangxi Returned Oversea Scholars (No. 0991004).

Supplementary Materials
Correlations among the factors.txt. (Supplementary Materials)

References
[1] N. J. Adderley, K. Nirantharakumar, and T. Marshall, “Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort study,” BMJ, vol. 361, 2018.
[2] R. G. Aleong, W. H. Sauer, G. Davis, and M. R. Bristow, “New-onset atrial fibrillation predicts heart failure progression,” The American Journal of Medicine, vol. 127, no. 10, pp. 963–971, 2014.
[3] E. J. Benjaman, P. Muntner, A. Alonso et al., “Heart disease and stroke statistics-2019 update: a report from the American Heart Association,” Circulation, vol. 139, no. 10, pp. e56–e528, 2019.
[4] S. P. Johnsen, L. W. Dalby, T. Täckström, J. Olsen, and A. Fraschke, “Cost of illness of atrial fibrillation: a nationwide study of societal impact,” BMC Health Services Research, vol. 17, no. 1, p. 714, 2017.
[5] K. H. Kuck, J. Brugada, A. Fünkranz et al., “Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation,” The New England Journal of Medicine, vol. 374, no. 23, pp. 2235–2245, 2016.
[6] N. F. Marrouche, J. Brachmann, D. Andresen et al., “Catheter ablation for atrial fibrillation with heart failure,” The New England Journal of Medicine, vol. 378, no. 5, pp. 417–427, 2018.
[7] S. Adamsson Erény, Y. Borné, O. Melander et al., “Red blood cell distribution width is associated with incidence of atrial fibrillation,” Journal of Internal Medicine, vol. 275, no. 1, pp. 84–92, 2014.
[8] L. C. Pilling, J. L. Atkins, G. A. Kuchel, L. Ferrucci, and D. Melzer, “Red cell distribution width and common disease onsets in 240,477 healthy volunteers followed for up to 9 years,” PLoS One, vol. 13, no. 9, article e0203504, 2018.
[9] Q. Shao, K. Chen, S. W. Rha, H. E. Lim, G. Li, and T. Liu, “Usefulness of neutrophil/lymphocyte ratio as a predictor of atrial fibrillation: a meta-analysis,” Archives of Medical Research, vol. 46, no. 3, pp. 199–206, 2015.
[10] A. Berkovitch, A. Younis, Y. Grossman et al., “Relation of neutrophil to lymphocyte ratio to risk of incident atrial fibrillation,” The American Journal of Cardiology, vol. 123, no. 3, pp. 396–401, 2019.
[11] B. Güngör, K. S. Özcan, I. Erdinler et al., “Elevated levels of RDW is associated with non-valvular atrial fibrillation,” Journal of Thrombosis and Thombolysis, vol. 37, no. 4, pp. 404–410, 2014.
[12] H. Gungor, A. S. Babu, C. Zencir et al., “Association of preoperative platelet-to-lymphocyte ratio with atrial fibrillation after coronary artery bypass graft surgery,” Medical principles and practice: international journal of the Kuwait University, Health Science Centre, vol. 26, no. 2, pp. 164–168, 2017.
[13] S. Dereli, A. Bayramoğlu, and O. C. Yontar, “Usefulness of platelet to lymphocyte ratio for predicting recurrence of atrial fibrillation after direct current cardioversion,” Annals of non-invasive electrocardiology, vol. 24, no. 2, article e12616, 2019.
[14] R. V. Navani, A. Baradi, K. L. Colin Huang et al., “Preoperative platelet-to-lymphocyte ratio is not associated with postoperative atrial fibrillation,” The Annals of Thoracic Surgery, vol. 110, no. 4, pp. 1265–1270, 2020.
[15] A. E. W. Johnson, T. J. Pollard, L. Shen et al., “MIMIC-III, a freely accessible critical care database,” Scientific data, vol. 3, 2016.
[16] A. S. Levey, J. Coresh, T. Greene et al., “Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values,” Clinical Chemistry, vol. 53, no. 4, pp. 766–772, 2007.
[17] S. Kubo, S. Nakayamada, K. Nakano et al., “Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; adjusted with propensity score matching,” Clinical immunology (Orlando, Fla), vol. 191, pp. 67–74, 2018.
[18] R. Desai, B. Hanna, S. Singh et al., “Trends and outcomes in sepsis hospitalizations with and without atrial fibrillation: a nationwide inpatient analysis,” Critical Care Medicine, vol. 47, no. 8, pp. e630–e638, 2019.
[19] P. M. Klein Klouwenberg, J. F. Frencken, S. Kuipers et al., “Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study,” American Journal of Respiratory and Critical Care Medicine, vol. 195, no. 2, pp. 205–211, 2017.
[20] C. J. Boos, R. A. Anderson, and G. Y. Lip, “Is atrial fibrillation an inflammatory disorder?,” European Heart Journal, vol. 27, no. 2, pp. 136–149, 2006.
[21] P. M. Ridker, B. M. Everett, T. Thuren et al., “Antinflammation therapy with canakinumab for atherosclerotic disease,” The New England Journal of Medicine, vol. 377, no. 12, pp. 1119–1131, 2017.
[22] J. Li, J. Solus, Q. Chen et al., “Role of inflammation and oxidative stress in atrial fibrillation,” Heart Rhythm, vol. 7, no. 4, pp. 438–444, 2010.
[23] Y. Ishii, R. B. Schuessler, S. L. Gaynor, K. Hames, and R. J. Damiano Jr., “Postoperative atrial fibrillation: the role of the inflammatory response,” The Journal of Thoracic and Cardiovascular Surgery, vol. 153, no. 6, pp. 1357–1365, 2017.
[24] C. Ruaengsri, M. R. Schill, T. S. Lancaster et al., “The hemodynamic and atrial electrophysiologic consequences of chronic left atrial volume overload in a controllable canine model,” The Journal of Thoracic and Cardiovascular Surgery, vol. 156, no. 5, pp. 1871–1879.e1, 2018.
[25] X. Cao, M. Aimoto, M. Fukushima, Y. Nagasawa, H. Tanaka, and A. Takahara, “Influence of chronic volume overload-induced atrial remodeling on electrophysiological responses to cholinergic receptor stimulation in the isolated rat atria,” Journal of Pharmacological Sciences, vol. 136, no. 2, pp. 73–78, 2018.
[26] J. Rodriguez-Carrio, M. Alperi-López, P. López, S. Alonso-Castro, F. J. Ballina-García, and A. Suárez, “Red cell distribution width is associated with cardiovascular risk and disease parameters in rheumatoid arthritis,” Rheumatology (Oxford, England), vol. 54, no. 4, pp. 641–646, 2015.
[27] M. da Silva Garrote-Filho, M. Bernardino-Neto, and N. Penha-Silva, “Influence of erythrocyte membrane stability in atherosclerosis,” Current Atherosclerosis Reports, vol. 19, no. 4, p. 17, 2017.
[28] B. Fujita, D. Strothoff, M. Fritzenwanger et al., “Altered red blood cell distribution width in overweight adolescents and its association with markers of inflammation,” Pediatric Obesity, vol. 8, no. 5, pp. 385–391, 2013.
[29] S. M. Parizadeh, R. Jafarzadeh-Esfahani, A. Bahreyni et al., “The diagnostic and prognostic value of red cell distribution width in cardiovascular disease; current status and prospective,” *BioFactors (Oxford, England)*, vol. 45, no. 4, pp. 507–516, 2019.

[30] A. Xanthopoulos, G. Giamouzis, A. Melidonis et al., “Red blood cell distribution width as a prognostic marker in patients with heart failure and diabetes mellitus,” *Cardiovascular Diabetology*, vol. 16, no. 1, p. 81, 2017.

[31] X. Z. Zhan, W. D. Lin, F. Z. Liu et al., “Predictive value of red cell distribution width on left atrial thrombus or left atrial spontaneous echo contrast in patients with non-valvular atrial fibrillation,” *Journal of geriatric cardiology: JGC*, vol. 15, no. 6, pp. 408–412, 2018.

[32] I. Jurin, I. Hadžibegović, I. Durlen et al., “Left atrium size and red cell distribution width predict atrial fibrillation progression from paroxysmal or persistent to permanent,” *Acta Clinica Belgica*, vol. 75, no. 3, pp. 205–211, 2020.

[33] G. Özgül, E. C. Seyhan, E. C. Seyhan, M. A. Özgül, and M. Z. Günlüoğlu, "Red blood cell distribution width in patients with chronic obstructive pulmonary disease and healthy subjects," *Archivos de bronconeumología*, vol. 53, no. 3, pp. 107–113, 2017.

[34] S. Y. Song, C. Hua, D. Dornbors et al., “Baseline red blood cell distribution width as a predictor of stroke occurrence and outcome: a comprehensive meta-analysis of 31 studies,” *Frontiers in neurology*, vol. 10, p. 1237, 2019.

[35] Q. Shao, P. Korantzopoulos, K. P. Letsas et al., “Red blood cell distribution width as a predictor of atrial fibrillation,” *Journal of Clinical Laboratory Analysis*, vol. 32, no. 5, article e22378, 2018.

[36] M. J. Cha, H. S. Lee, H. M. Kim, J. H. Jung, E. K. Choi, and S. Oh, “Association between red cell distribution width and thromboembolic events in patients with atrial fibrillation,” *European Journal of Internal Medicine*, vol. 46, pp. 41–46, 2017.

[37] J. E. Siegler, C. Marcaccio, K. Nawalinski et al., “Elevated red cell distribution width is associated with cerebral infarction in aneurysmal subarachnoid hemorrhage,” *Neurocritical Care*, vol. 26, no. 1, pp. 26–33, 2017.

[38] G. L. Salvagno, F. Sanchis-Gomar, A. Picanza, and G. Lippi, “Red blood cell distribution width: a simple parameter with multiple clinical applications,” *Critical Reviews in Clinical Laboratory Sciences*, vol. 52, no. 2, pp. 86–105, 2015.

[39] J. Pan, Y. Borné, and G. Engström, “The relationship between red cell distribution width and all-cause and cause-specific mortality in a general population,” *Scientific Reports*, vol. 9, no. 1, p. 16208, 2019.

[40] K. H. Lee, J. G. Cho, H. W. Park, N. S. Yoon, H. K. Jeong, and N. Lee, “Role of red cell distribution width in the relationship between clinical outcomes and antiocoagulation response in patients with atrial fibrillation,” *Chonnam Medical Journal*, vol. 54, no. 2, pp. 113–120, 2018.

[41] B. H. Foy, J. C. T. Carlson, E. Reinertsen et al., “Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection,” *JAMA Network Open*, vol. 3, no. 9, article e2022058, 2020.

[42] Z. Yan, Y. Fan, Z. Meng et al., “The relationship between red blood cell distribution width and metabolic syndrome in elderly Chinese: a cross-sectional study,” *Lipids in Health and Disease*, vol. 18, no. 1, p. 34, 2019.

[43] Y. G. Kim, K. D. Han, J. I. Choi et al., “The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study,” *Cardiovascular Diabetology*, vol. 18, no. 1, p. 128, 2019.

[44] L. Guo, X. Liu, P. Yu, and W. Zhu, “The "obesity paradox" in patients with HFpEF with or without comorbid atrial fibrillation,” *Frontiers in cardiovascular medicine*, vol. 8, 2021.

[45] G. Bazoukis, K. P. Letsas, K. Vlachos et al., “Simple hematological predictors of AF recurrence in patients undergoing atrial fibrillation ablation,” *Journal of geriatric cardiology: JGC*, vol. 16, no. 9, pp. 671–675, 2019.

[46] K. J. Walsh, K. S. Tan, H. Zhang, and D. Amar, “Neutrophil-lymphocyte ratio and risk of atrial fibrillation after thoracic surgery,” *Interactive Cardiovascular and Thoracic Surgery*, vol. 24, no. 4, pp. 555–559, 2017.

[47] R. C. Weedle, M. Da Costa, D. Veerasingam, and A. W. S. Soo, “The use of neutrophil lymphocyte ratio to predict complications post cardiac surgery,” *Annals of translational medicine*, vol. 7, no. 23, p. 778, 2019.

[48] A. Kurtul and E. Ornek, “Platelet to lymphocyte ratio in cardiovascular diseases: a systematic review,” *Angiology*, vol. 70, no. 9, pp. 802–818, 2019.

[49] A. Maimaiti, Y. Li, Y. T. Wang et al., “Association of platelet-to-lymphocyte count ratio with myocardial reperfusion and major adverse events in patients with acute myocardial infarction: a two-centre retrospective cohort study,” *BMJ Open*, vol. 9, no. 9, article e025628, 2019.

[50] Y. Luo, J. Zhang, T. Liu et al., “The systemic-immune-inflammation index predicts the recurrence of atrial fibrillation after cryomaze concomitant with mitral valve surgery,” *BMC Cardiovascular Disorders*, vol. 22, no. 1, p. 45, 2022.

[51] B. Ding, P. Liu, F. Zhang, J. Hui, and L. He, “Predicting values of neutrophil-to-lymphocyte ratio (NLR), high-sensitivity C-reactive protein (hs-CRP), and left atrial diameter (LAD) in patients with nonvalvular atrial fibrillation recurrence after radiofrequency ablation,” *Medicina science monitor: international medical journal of experimental and clinical research*, vol. 28, article e934569, 2022.

[52] W. Zhu, P. Yuan, Y. Shen, R. Wan, and K. Hong, “Association of smoking with the risk of incident atrial fibrillation: a meta-analysis of prospective studies,” *International Journal of Cardiology*, vol. 218, pp. 259–266, 2016.

[53] C. A. Groh, E. Vittinghoff, E. J. Benjamini, J. Dupuis, and G. M. Marcus, “Childhood tobacco smoke exposure and risk of atrial fibrillation in adulthood,” *Journal of the American College of Cardiology*, vol. 74, no. 13, pp. 1658–1664, 2019.

[54] A. Voskoboinik, J. M. Kalman, A. De Silva et al., “Alcohol abstinence in drinkers with atrial fibrillation,” *The New England Journal of Medicine*, vol. 382, no. 1, pp. 20–28, 2020.

[55] D. Csengeri, N. A. Sprünker, A. Di Castelnuovo et al., “Annual review: platelet aggregation,” *Annual Review of Nutrition*, vol. 31, pp. 1–26, 2011.

[56] J. Heijman, D. Linz, and U. Schotten, “Dynamics of atrial fibrillation mechanisms and comorbidities,” *Annual Review of Physiology*, vol. 83, no. 1, pp. 83–106, 2021.